Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00750 (
PLA
)
16,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Phospholipases A(2) (
PLA
(2)) are ubiquitous enzymes involved in membrane fatty acid metabolism and intracellular signalling. Recent studies have shown that
PLA
(2) subtypes are implicated in the modulation of pathways related to memory acquisition and retrieval. We investigated the effects of cognitive training on platelet
PLA
(2) activity in healthy elderly individuals. Twenty-three cognitively unimpaired older adults were randomly assigned to receive memory training or standard outpatient care only. Both groups were cognitively assessed by the same protocol, and the experimental group (EG) underwent a four-session memory training intervention. Pre- and post-test measures included prose and list recall, WAIS-III digit symbol, strategy use measures and platelet
PLA
(2) group activity. After cognitive training, patients in the EG group had significant increase in
cytosolic, calcium-dependent
PLA
(2) (cPLA(2)), extracellular (or secreted), calcium-dependent
PLA
(2) (sPLA(2)), total platelet
PLA
(2) activity, and significant decrease in platelet calcium-independent
PLA
(2) (iPLA(2)) activity. Our results suggest that memory training may have a modulating effect in
PLA
(2)-mediated biological systems associated with cognitive functions and neurodegenerative diseases.
...
PMID:Cognitive training increases platelet PLA2 activity in healthy elderly subjects. 1846 85
Lung cancer remains the leading cause of cancer deaths in the United States and the rest of the world. The advent of molecularly directed therapies holds promise for improvement in therapeutic efficacy.
Cytosolic phospholipase A2
(
cPLA2
) is associated with tumor progression and radioresistance in mouse tumor models. Utilizing the
cPLA2
specific inhibitor
PLA
-695, we determined if
cPLA2
inhibition radiosensitizes non small cell lung cancer (NSCLC) cells and tumors. Treatment with
PLA
-695 attenuated radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. NSCLC cells (LLC and A549) co-cultured with endothelial cells (bEND3 and HUVEC) and pre-treated with
PLA
-695 showed radiosensitization.
PLA
-695 in combination with irradiation (IR) significantly reduced migration and proliferation in endothelial cells (HUVEC & bEND3) and induced cell death and attenuated invasion by tumor cells (LLC &A549). In a heterotopic tumor model, the combination of
PLA
-695 and radiation delayed growth in both LLC and A549 tumors. LLC and A549 tumors treated with a combination of
PLA
-695 and radiation displayed reduced tumor vasculature. In a dorsal skin fold model of LLC tumors, inhibition of
cPLA2
in combination with radiation led to enhanced destruction of tumor blood vessels. The anti-angiogenic effects of
PLA
-695 and its enhancement of the efficacy of radiotherapy in mouse models of NSCLC suggest that clinical trials for its capacity to improve radiotherapy outcomes are warranted.
...
PMID:Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models. 2389 23